Monopar Therapeutics (MNPR) Competitors $20.10 +0.39 (+1.98%) (As of 11/22/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestTrends MNPR vs. VTGN, PTI, CTXR, DARE, MACK, AQST, CGC, LRMR, AKBA, and TNGXShould you be buying Monopar Therapeutics stock or one of its competitors? The main competitors of Monopar Therapeutics include Vistagen Therapeutics (VTGN), Proteostasis Therapeutics (PTI), Citius Pharmaceuticals (CTXR), Daré Bioscience (DARE), Merrimack Pharmaceuticals (MACK), Aquestive Therapeutics (AQST), Canopy Growth (CGC), Larimar Therapeutics (LRMR), Akebia Therapeutics (AKBA), and Tango Therapeutics (TNGX). These companies are all part of the "medical" sector. Monopar Therapeutics vs. Vistagen Therapeutics Proteostasis Therapeutics Citius Pharmaceuticals Daré Bioscience Merrimack Pharmaceuticals Aquestive Therapeutics Canopy Growth Larimar Therapeutics Akebia Therapeutics Tango Therapeutics Vistagen Therapeutics (NASDAQ:VTGN) and Monopar Therapeutics (NASDAQ:MNPR) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, community ranking, profitability, earnings, dividends, media sentiment, valuation, risk and institutional ownership. Is VTGN or MNPR more profitable? Monopar Therapeutics has a net margin of 0.00% compared to Vistagen Therapeutics' net margin of -4,521.71%. Vistagen Therapeutics' return on equity of -36.35% beat Monopar Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Vistagen Therapeutics-4,521.71% -36.35% -33.62% Monopar Therapeutics N/A -107.21%-87.57% Does the MarketBeat Community believe in VTGN or MNPR? Vistagen Therapeutics received 240 more outperform votes than Monopar Therapeutics when rated by MarketBeat users. However, 72.41% of users gave Monopar Therapeutics an outperform vote while only 72.31% of users gave Vistagen Therapeutics an outperform vote. CompanyUnderperformOutperformVistagen TherapeuticsOutperform Votes28272.31% Underperform Votes10827.69% Monopar TherapeuticsOutperform Votes4272.41% Underperform Votes1627.59% Which has stronger valuation & earnings, VTGN or MNPR? Monopar Therapeutics has lower revenue, but higher earnings than Vistagen Therapeutics. Monopar Therapeutics is trading at a lower price-to-earnings ratio than Vistagen Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVistagen Therapeutics$1.06M67.76-$29.36M-$1.24-2.08Monopar TherapeuticsN/AN/A-$8.40M-$1.97-10.20 Which has more risk and volatility, VTGN or MNPR? Vistagen Therapeutics has a beta of 0.78, meaning that its share price is 22% less volatile than the S&P 500. Comparatively, Monopar Therapeutics has a beta of 1.09, meaning that its share price is 9% more volatile than the S&P 500. Does the media prefer VTGN or MNPR? In the previous week, Monopar Therapeutics had 3 more articles in the media than Vistagen Therapeutics. MarketBeat recorded 4 mentions for Monopar Therapeutics and 1 mentions for Vistagen Therapeutics. Vistagen Therapeutics' average media sentiment score of 0.96 beat Monopar Therapeutics' score of 0.72 indicating that Vistagen Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vistagen Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Monopar Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals & insiders hold more shares of VTGN or MNPR? 78.4% of Vistagen Therapeutics shares are held by institutional investors. Comparatively, 1.8% of Monopar Therapeutics shares are held by institutional investors. 1.3% of Vistagen Therapeutics shares are held by company insiders. Comparatively, 34.9% of Monopar Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Do analysts recommend VTGN or MNPR? Vistagen Therapeutics presently has a consensus target price of $15.00, indicating a potential upside of 481.40%. Monopar Therapeutics has a consensus target price of $27.33, indicating a potential upside of 35.99%. Given Vistagen Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe Vistagen Therapeutics is more favorable than Monopar Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Vistagen Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50Monopar Therapeutics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryVistagen Therapeutics beats Monopar Therapeutics on 11 of the 18 factors compared between the two stocks. Ad Darwin2024 Election Year Stocks: Uncover Hidden Gems!In the lead-up to the pivotal 2024 election year, we're excited to present our comprehensive report, "Election Year Investment Gems: Stock Poised To Takeoff In 2024," brimming with insights and opportunities you won't want to miss.Secure your copy now by clicking this link. Get Monopar Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for MNPR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MNPR vs. The Competition Export to ExcelMetricMonopar TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$106.09M$7.00B$5.38B$8.84BDividend YieldN/A8.11%5.13%4.09%P/E Ratio-10.2011.01105.0417.81Price / SalesN/A361.871,235.79158.52Price / CashN/A52.5940.3536.29Price / Book21.3810.377.086.50Net Income-$8.40M$153.60M$119.58M$226.22M7 Day Performance11.11%4.59%2.25%4.03%1 Month Performance334.13%-6.28%-2.34%4.92%1 Year Performance1,200.97%33.39%33.95%29.30% Monopar Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MNPRMonopar Therapeutics3.5754 of 5 stars$20.10+2.0%$27.33+36.0%+1,201.0%$106.09MN/A-10.2010VTGNVistagen Therapeutics3.7095 of 5 stars$2.54-2.7%$15.00+490.6%-23.0%$74.34M$1.06M0.0040PTIProteostasis TherapeuticsN/AN/AN/AN/A$37.57M$5M-0.6244Gap UpCTXRCitius Pharmaceuticals2.9469 of 5 stars$0.17flat$4.00+2,322.8%-82.6%$29.84MN/A-0.6920Stock SplitNews CoverageGap DownHigh Trading VolumeDAREDaré Bioscience2.2311 of 5 stars$3.23+1.6%$24.00+643.0%-16.1%$27.67M$1.88M-5.4730MACKMerrimack PharmaceuticalsN/A$15.13flatN/AN/A$223.77MN/A1.09426Analyst ForecastAQSTAquestive Therapeutics2.2799 of 5 stars$4.56-3.8%$9.80+115.1%+123.5%$415.33M$50.58M-10.52160Positive NewsCGCCanopy Growth1.3455 of 5 stars$3.87+2.9%$3.50-9.4%-32.4%$407.22M$220.27M-0.781,029LRMRLarimar Therapeutics3.7065 of 5 stars$6.13+0.8%$20.43+233.3%+85.5%$407.09MN/A0.0030Analyst ForecastAKBAAkebia Therapeutics3.9371 of 5 stars$1.82+1.7%$5.75+215.9%+89.9%$390.54M$169.88M-7.91167Analyst DowngradeTNGXTango Therapeutics2.4934 of 5 stars$3.63-11.0%$13.14+262.1%-49.6%$389.94M$36.53M-3.0890High Trading Volume Related Companies and Tools Related Companies Vistagen Therapeutics Alternatives Proteostasis Therapeutics Alternatives Citius Pharmaceuticals Alternatives Daré Bioscience Alternatives Merrimack Pharmaceuticals Alternatives Aquestive Therapeutics Alternatives Canopy Growth Alternatives Larimar Therapeutics Alternatives Akebia Therapeutics Alternatives Tango Therapeutics Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:MNPR) was last updated on 11/23/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | Sponsored⭕ [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.Behind the Markets | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Monopar Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Monopar Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free MNPR Stock Alerts